The potential role of Aurora kinase inhibitors in haematological malignancies.
The potential role of Aurora kinase inhibitors in haematological malignancies.
复制标题
DOI：
10.1111/j.1365-2141.2011.08898.x
复制
发表时间：
2011-12
影响因子：
6.5
通讯作者：
Farag SS
中科院分区：
文献类型：
--
作者：
Farag SS
极光激酶在细胞周期的控制中起重要作用，并与许多癌症的肿瘤发生有关。在血液恶性肿瘤中，Aurora激酶的过表达已在急性髓性白血病、慢性髓性白血病、急性淋巴母细胞白血病、多发性骨髓瘤、侵袭性非霍奇金淋巴瘤和霍奇金淋巴瘤中报道。大量的极光激酶抑制剂目前处于不同的临床开发阶段。除了对不同Aurora激酶的选择性不同之外，一些还具有针对参与癌细胞中重要分子途径的其他细胞激酶的活性。本文综述了极光激酶的生物学，并讨论了为什么它们可能是不同血液系统癌症的良好治疗靶点。我们描述了临床前数据，已作为调查极光激酶抑制剂在不同的血液系统恶性肿瘤的基本原理，并总结了早期临床试验的结果。虽然Aurora激酶抑制剂的抗肿瘤作用似乎很有希望，但我们强调了未来临床研究的重要问题，并建议这些抑制剂的最佳使用可能是与已经用于治疗各种血液癌症的细胞毒性药物联合使用。
Aurora kinases play an important role in the control of the cell cycle and have been implicated in tumourigenesis in a number of cancers. Among the haematological malignancies, overexpression of Aurora kinases has been reported in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia, multiple myeloma, aggressive non-Hodgkin lymphoma and Hodgkin lymphoma. A large number of Aurora kinase inhibitors are currently in different stages of clinical development. In addition to varying in their selectivity for the different Aurora kinases, some also have activity directed at other cellular kinases involved in important molecular pathways in cancer cells. This review summarizes the biology of Aurora kinases and discusses why they may be good therapeutic targets in different haematological cancers. We describe preclinical data that has served as the rationale for investigating Aurora kinase inhibitors in different haematological malignancies, and summarize published results from early phase clinical trials. While the anti-tumour effects of Aurora kinase inhibitors appear promising, we highlight important issues for future clinical research and suggest that the optimal use of these inhibitors is likely to be in combination with cytotoxic agents already in use for the treatment of various haematological cancers.
登录
查看更多内容
影响因子：
20.3
作者：
Chesi, M;Brents, LA;Bergsagel, PL
通讯作者：
Bergsagel, PL
DOI：
10.1073/pnas.0701140104
发表时间：
2007-03-13
影响因子：
11.1
作者：
Burkard, Mark E.;Randall, Catherine L.;Jallepalli, Prasad V.
通讯作者：
Jallepalli, Prasad V.
影响因子：
9.8
作者：
Burkard ME;Maciejowski J;Rodriguez-Bravo V;Repka M;Lowery DM;Clauser KR;Zhang C;Shokat KM;Carr SA;Yaffe MB;Jallepalli PV
通讯作者：
Jallepalli PV
影响因子：
9.7
作者：
Bodvarsdottir, Sigridur K.;Hilmarsdottir, Holmfridur;Eyfjord, Jorunn E.
通讯作者：
Eyfjord, Jorunn E.
影响因子：
6.4
作者：
Camacho, E;Beà, S;Hernández, L
通讯作者：
Hernández, L